David Sallman, MD, assistant member in the Department of Malignant Hematology at Moffitt Cancer Center, discusses the key factors for patients with AML to consider when making treatment decisions with their care team. Key factors include their overall health and fitness level, the presence of mutations or other molecular changes that may impact AML, and the patient’s preference. Dr Sallmann suggests that it is important for patients to ask why a particular treatment regimen is selected, the implications of mutations, potential availability of clinical trials, and the need to seek a second opinion.